Viatris to acquire Pacira BioSciences for $1.65 billion, expanding its non‑opioid pain portfolio

Viatris, a maker of generic and branded medicines, announced a cash purchase of commercial‑stage Pacira BioSciences for $1.65 billion. The deal adds Pacira’s non‑opioid pain treatments to Viatris’ growing pain‑management lineup.

The acquisition is being positioned as a strategic move to strengthen Viatris’ presence in the pain‑relief market, which has seen increased demand for alternatives to opioid therapies.

Both companies expect the transaction to close later this year, subject to customary regulatory approvals and closing conditions.

Analysts view the purchase as a positive step for Viatris, potentially boosting its revenue streams and market share in the competitive pain‑care sector.